What is UroGen Pharma's operating income?

UroGen Pharma (URGN) reported operating income of -$22.82M in Q2 2021.

What does operating income mean?

Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

UroGen Pharma URGN Operating Income

Discontinued — last reported Q2 '21

Operating Income at other companies

ImmunityBio, Inc.IBRX

-$69.79M-8.3%

Tyra Biosciences, Inc.TYRA

-$42M-31.9%

CG OncologyCGON

-$66.39M-57.3%

ImmunomeIMNM

-$59.33M-32.9%

Ultragenyx PharmaceuticalRARE

-$169M-18.2%

Johnson & JohnsonJNJ

——

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.71B+71.7%

Enterprise value$1.8B+80.9%

P/S12.2×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: UroGen Pharma’s 10-Q, filed August 4, 2021, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's operating income?: UroGen Pharma (URGN) reported operating income of -$22.82M in Q2 2021.
What does operating income mean?: Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.